XNAS · Healthcare · Biotechnology
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.56 | -0.57 | -1.79% | $0 | ❌ Miss | -8.18% | -24.55% | -20.73% |
| 2026-03-05 | Q4 2025 | -0.48 | -0.57 | -18.75% | $0 | ❌ Miss | -1.65% | +15.09% | +8.68% |
| 2025-11-12 |
| Q3 2025 |
| -0.43 |
| -0.53 |
| -23.26% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.43 | -0.44 | -2.33% | $0 | ❌ Miss | +4.05% | +0.87% | -2.60% |
| 2025-03-06 | Q4 2024 | -0.29 | -0.40 | -37.93% | $0 | ❌ Miss | -0.33% | +2.00% | -7.33% |
| 2024-11-07 | Q3 2024 | -0.49 | -0.37 | +24.49% | $0 | ✅ Beat | +1.74% | -3.78% | -12.21% |
| 2024-08-07 | Q2 2024 | -0.76 | -0.48 | +36.84% | $0 | ✅ Beat | +7.03% | +10.09% | +10.09% |
| 2024-05-14 | Q1 2024 | -0.61 | -0.75 | -22.95% | $0 | ❌ Miss | -6.31% | -8.84% | -6.57% |
Showing last 8 quarters.